Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (NYSE: PTHS) is a biopharmaceutical company commercializing prescription products and developing potential therapies for skin conditions and pain. Its commercial portfolio includes ZELSUVMI, a topical gel for molluscum contagiosum launched in the United States in July 2025; XEPI, a cream for… From the company’s description.
In fiscal 2025, Pelthos Therapeutics Inc. reported revenue of $16.80M and a net loss of $43.32M. Its operating margin was −193.1%, and operations used $22.59M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pelthos Therapeutics Inc. does
In the company’s own words
Pelthos Therapeutics Inc. (NYSE: PTHS) is a biopharmaceutical company commercializing prescription products and developing potential therapies for skin conditions and pain. Its commercial portfolio includes ZELSUVMI, a topical gel for molluscum contagiosum launched in the United States in July 2025; XEPI, a cream for impetigo; and XEGLYZE, a treatment for head lice. The latter two products were acquired in 2025, with relaunch and launch activities planned, respectively. Pelthos markets ZELSUVMI to pediatricians, pediatric dermatologists and dermatologists, distributing it through retail and mail-order pharmacies and Amazon Pharmacy. The company also has clinical-stage programs targeting the NaV1.7 sodium channel for eye, postoperative and neuropathic pain, and manufactures berdazimer sodium, the active ingredient in ZELSUVMI, at its North Carolina facility. Pelthos was formed in July 2025 through the merger of Channel Therapeutics and LNHC, bringing together commercial products, manufacturing capabilities and pain-development assets. Its website is www.pelthostherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- December
- CIK
- 1919246
- SIC
- 2836
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pelthos Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pelthos Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pelthos Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pelthos Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pelthos Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”